These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ophthalmic levocabastine for allergic conjunctivitis. Med Lett Drugs Ther; 1994 Apr; 36(920):35-6. PubMed ID: 7908401 [No Abstract] [Full Text] [Related]
8. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Secchi A; Leonardi A; Discepola M; Deschenes J; Abelson MB Acta Ophthalmol Scand Suppl; 2000; (230):48-51. PubMed ID: 11057351 [TBL] [Abstract][Full Text] [Related]
9. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Abelson MB; Weintraub D Eur J Ophthalmol; 1994; 4(2):91-101. PubMed ID: 7950341 [TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Azevedo M; Castel-Branco MG; Oliveira JF; Ramos E; Delgado L; Almeida J Clin Exp Allergy; 1991 Nov; 21(6):689-94. PubMed ID: 1685691 [TBL] [Abstract][Full Text] [Related]
11. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Giede C; Metzenauer P; Petzold U; Ellers-Lenz B Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004 [TBL] [Abstract][Full Text] [Related]
12. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Netland PA; Leahy C; Krenzer KL Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis. Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252 [TBL] [Abstract][Full Text] [Related]
15. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Richard C; Trinquand C; Bloch-Michel E Eur J Ophthalmol; 1998; 8(4):207-16. PubMed ID: 9891891 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. Abelson MB; George MA; Schaefer K; Smith LM J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020 [TBL] [Abstract][Full Text] [Related]
17. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Bende M; Pipkorn U Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of levocabastine in conjunctival provocation studies. Janssens M Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Secchi A; Ciprandi G; Leonardi A; Deschenes J; Abelson MB Acta Ophthalmol Scand Suppl; 2000; (230):42-7. PubMed ID: 11057350 [TBL] [Abstract][Full Text] [Related]
20. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Janssens MM Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]